Pfizer Inc. - PFE STOCK NEWS

Pfizer and BioNTech have announced a collaboration to develop an mRNA-based vaccine for shingles, targeting the herpes zoster virus. This partnership marks their third collaboration in infectious diseases, building on their previous successes with COVID-19 and influenza vaccines. Under the agreement, BioNTech will receive $225 million upfront, while Pfizer will secure $25 million for its proprietary antigen sequences. Clinical trials are set to begin in the second half of 2022, with cost-sharing and profit-sharing on potential vaccine sales.

Pfizer Inc. (NYSE: PFE) has announced a commitment from the U.S. government to purchase an additional 10 million treatment courses of its COVID-19 oral therapy, PAXLOVID™ (nirmatrelvir and ritonavir). This raises the total to 20 million courses, with 10 million set for accelerated delivery by June and the remaining by September 2022. PAXLOVID is FDA authorized for emergency use in high-risk adults and pediatric patients. Pfizer is also increasing production projections from 80 million to 120 million courses for 2022, to meet global demand amid the surge of the Omicron variant.

Pfizer Inc. (NYSE: PFE) invites the public to a webcast featuring CEO Albert Bourla at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:00 p.m. EST. Interested individuals can access the webcast on Pfizer's investor relations website. A transcript and replay will be available within 24 hours and accessible for 90 days. Pfizer emphasizes its commitment to innovative healthcare solutions over its 170-year history, actively working to enhance accessibility to treatments and vaccines worldwide.

The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include booster doses for individuals aged 12 and older. The booster maintains the same 30-µg dosage as the primary series, addressing rising COVID-19 cases. Additionally, the waiting time for the booster after primary series completion has been reduced from six to five months. A third primary series dose is also authorized for immunocompromised children aged 5-11. Pfizer and BioNTech have delivered 1 billion doses to low- and middle-income countries, with an additional billion expected in 2022.

Pfizer Inc. (NYSE: PFE) will host a webcast featuring Albert Bourla, Chairman and CEO, at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, at 10:00 a.m. EST. Investors and the public can join the discussion by visiting www.pfizer.com/investors. A transcript and replay will be available within 24 hours and accessible for 90 days. Pfizer continues its commitment to advancing healthcare and collaborating globally to improve patient lives.

Pfizer (NYSE: PFE) will host a conference call for investors at 10 a.m. EST on February 8, 2022, to discuss its Fourth Quarter and Full Year 2021 Performance Report. The report will be released that morning. Interested parties can access the webcast and report on www.pfizer.com/investors. For audio access, dial (833) 708-1779 in the U.S. or (602) 585-9859 internationally, using the passcode “020822”. A transcript and replay will be available for 90 days after the call.

Pfizer Inc. (NYSE: PFE) announced that the FDA has authorized emergency use of PAXLOVID™ for high-risk patients aged 12 and older with COVID-19. Clinical data from the EPIC-HR study shows PAXLOVID reduces hospitalization or death by 89% within three days of symptom onset. Pfizer plans immediate U.S. delivery and has increased production from 80 million to 120 million treatment courses by the end of 2022 due to demand. Additionally, Pfizer aims for full FDA approval in 2022 and has agreements with various countries for equitable access to the treatment.

Pfizer (NYSE: PFE) announced an agreement with the UK government for an additional 2.5 million doses of PAXLOVID™, bringing the total to 2.75 million doses, subject to regulatory approval. PAXLOVID, an investigational antiviral, has shown to reduce hospitalization risk by nearly 90% in high-risk patients. Pfizer expects to manufacture up to 80 million courses by year-end. The company is committed to equitable access and has invested approximately $1 billion in manufacturing and distribution efforts, collaborating with around 100 countries and signing agreements to expand access in low- and middle-income nations.

ViiV Healthcare has received FDA approval for Apretude, a long-acting injectable HIV pre-exposure prophylaxis (PrEP), the first of its kind to show superior efficacy compared to daily oral options. It is indicated for adults and adolescents over 35 kg at risk of HIV. Apretude can be administered as few as six times a year, with studies showing a 69% to 90% lower incidence of HIV compared to daily oral options. This innovative treatment addresses the needs of vulnerable populations, particularly in Black and Latinx communities, providing an alternative to daily pills.